TP53 and myelodysplastic syndrome: When predicting p53 activity (based on TP53 R72P and MDM2 SNP309), it was demonstrated that non-del(5q) MDS patients with a high p53 SNP activity had a significantly longer overall survival (OS) and progression-free survival (PFS) compared to patients with a low p53 SNP activity [6,29,30] (Figure 1C).